IP Library Granted Patent US 7,659,257
Granted Patent B2
US 7,659,257 · App. 10/466,491 · Granted Feb 9, 2010

Medicament for treating lung cancer

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,659,257
App. No.
10/466,491
Granted
Feb 9, 2010
Kind
B2
Abstract

Lung cancer can be treated effectively by combination of amrubicin or a pharmaceutically acceptable salt thereof with cisplatin.

Claims (17)

1. A method for treating a lung cancer which comprises administering to a patient in need thereof an effective amount of amrubicin or a pharmaceutically acceptable salt thereof and cisplatin.

2. The method for treating lung cancer as described in claim 1 , wherein the lung cancer is small cell lung cancer, lung adenocarcinoma, squamous cell lung carcinoma or large cell lung carcinoma.

3. The method for treating lung cancer as described in claim 1 , wherein the lung cancer is small cell lung cancer.

4. The method for treating lung cancer as described in claim 1 , wherein the amrubicin or a pharmaceutically acceptable salt thereof is amrubicin hydrochloride.

5. The method for treating lung cancer as described in claim 1 , wherein amrubicin or a pharmaceutically acceptable salt thereof is administered simultaneously with cisplatin.

6. The method for treating lung cancer as described in claim 1 , wherein amrubicin or a pharmaceutically acceptable salt thereof is administered separately or sequentially with cisplatin.

7. The method for treating lung cancer as described in claim 1 , for a patient carrying a lung cancer to which cisplatin has been administered or is planned to be administered.

8. The method for treating lung cancer as described in claim 1 , wherein about 60 to about 135 mg/m 2 of amrubicin or a pharmaceutically acceptable salt thereof is administered in a single dose or in 2 to 5 divided doses.

9. The method for treating lung cancer as described in claim 8 , wherein about 110 to about 130 mg/m 2 of amrubicin or a pharmaceutically acceptable salt thereof is administered in a single dose.

10. The method for treating lung cancer as described in claim 8 , wherein about 25 to about 50 mg/m 2 of amrubicin or a pharmaceutically acceptable salt thereof is administered once a day for 3 days.

11. The method for treating lung cancer as described in claim 8 , wherein about 35 to about 45 mg/m 2 of amrubicin or a pharmaceutically acceptable salt thereof is administered once a day for 3 days.

12. The method for treating lung cancer as described in claim 10 or 11 , wherein amrubicin or a pharmaceutically acceptable salt thereof is administered for continuous 3 days.

13. The method for treating lung cancer as described in any of claims 8 to 11 , wherein about 35 to about 90 mg/m 2 of cisplatin is administered in a single dose.

14. The method for treating lung cancer as described in claim 13 , wherein about 50 to about 70 mg/m 2 of cisplatin is administered in a single dose.

15. The method for treating lung cancer as described in claim 1 , for a patient having a lung cancer, wherein the patient is one having failed prior treatment with cisplatin because of side effects, and wherein cisplatin is administered to said patient in an amount that will cause reduced side effects.

16. The method for treating lung cancer as described in claim 1 , wherein the lung cancer is one in which carbonyl reductase-1 is expressed at a level at least two-fold greater than the level in normal lung tissue.

17. A method for treating a lung cancer which comprises administering to a patient having a lung cancer in which carbonyl reductase-1 is expressed at a level at least two-fold greater than the level in normal lung tissue an effective amount of amrubicin or a pharmaceutically acceptable salt thereof and cisplatin.

Assignments (2)
MERGER Recorded Dec 16, 2005
From: SUMITOMO PHARMACEUTICALS COMPANY, LTD.
To: DAINIPPON SUMITOMO PHARMA CO., LTD.
Reel/Frame 017089/0420 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2003
From: NOGUCHI, TOSHIHIRO; BABA, AKEMI
To: SUMITOMO PHARMACEUTICALS COMPANY, LIMITED
Reel/Frame 014549/0008 →